Revenue distribution of CanSino Biologics Inc. 2021, by market

Published by
Wenyi Zhang,
Sep 4, 2024
In 2021, more than 70 percent of CanSino's 4.3 billion yuan revenue was generated by the international market. Thanks to the export sales of Convidecia, the company's single-dose COVID-19 vaccine, CanSino increased its annual revenue by more than 23,000 percent in 2021 and became a profitable business for the first time in many years.

Annual revenue distribution of CanSino Biologics Inc. in 2021, by market

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2022

Region

China

Survey time period

2021

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Chinese COVID-19 vaccines "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Chinese COVID-19 vaccines

Overview

6

Sinovac

6

Sinopharm and CanSino

6

Domestic adoption

5

Exports

5

Further Content: You might find this interesting as well

Topics

Chinese COVID-19 vaccinesCoronavirus COVID-19 in ChinaPharmaceutical industry in ChinaVaccine industry in ChinaCoronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.